| 000 | 01887 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513052722.0 | ||
| 264 | 0 | _c19941228 | |
| 008 | 199412s 0 0 eng d | ||
| 022 | _a1073-449X | ||
| 024 | 7 |
_a10.1164/ajrccm.150.6.7952606 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJones, B E | |
| 245 | 0 | 0 |
_aA prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. _h[electronic resource] |
| 260 |
_bAmerican journal of respiratory and critical care medicine _cDec 1994 |
||
| 300 |
_a1499-502 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xdrug therapy |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntitubercular Agents _xadverse effects |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEthambutol _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHIV-1 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoniazid _xadministration & dosage |
| 650 | 0 | 4 |
_aLos Angeles _xepidemiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMycobacterium tuberculosis _xisolation & purification |
| 650 | 0 | 4 | _aPatient Compliance |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aPyrazinamide _xadministration & dosage |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 |
_aRifampin _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTuberculosis, Pulmonary _xdrug therapy |
| 700 | 1 | _aOtaya, M | |
| 700 | 1 | _aAntoniskis, D | |
| 700 | 1 | _aSian, S | |
| 700 | 1 | _aWang, F | |
| 700 | 1 | _aMercado, A | |
| 700 | 1 | _aDavidson, P T | |
| 700 | 1 | _aBarnes, P F | |
| 773 | 0 |
_tAmerican journal of respiratory and critical care medicine _gvol. 150 _gno. 6 Pt 1 _gp. 1499-502 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1164/ajrccm.150.6.7952606 _zAvailable from publisher's website |
| 999 |
_c7951937 _d7951937 |
||